CA199和CEA联合检测对肠道恶性肿瘤术后复发的诊断价值
陈艳宁,李焕春,钟志, 哈尔滨医科大学附属肿瘤医院检验科 黑龙江省哈尔滨市 150040
姜季, 哈尔滨医科大学附属肿瘤医院核医学 黑龙江省哈尔滨市 150040
通讯作者:陈艳宁,150040, 黑龙江省哈尔滨市南岗区哈平路150号,哈尔滨医科大学附属肿瘤医院检验科. duzj01@hit.edu.cn
电话: 0451-86627491
收稿日期:2005-04-11 接受日期:2005-04-27
摘要目的:探讨低聚糖类抗原(CA199)和癌胚抗原(CEA)两种标志物联合检测对肠道恶性肿瘤术后复发转移的早期诊断价值.
, http://www.100md.com
方法:微粒子酶免发光法(MEIA)测定32例肠道恶性肿瘤患者外周血CA199和CEA，实验结果结合临床资料进行分析.
结果:肠道恶性肿瘤术后患者转移复发组CEA、CA199明显高于无复发转移组(P<0.05).平行实验灵敏度为:78.52%;特异性:84.21%;阳性预测值:77.27%;临床疑似率:78.13%;系列实验灵敏度:60.00%;特异性:94.12%;阳性预测值:90.00%;临床疑似率:81.25%.单项测定结果:CEA灵敏度为60.71%;特异性:86.84%;阳性预测值:77.27%;临床疑似率:71.87%.CA199灵敏度为64.29;特异性:94.74%;阳性预测值:90.00%;临床疑似率:84.38%.
结论:外周血CA199与CEA对肠道恶性肿瘤术后转移复发的早期诊断有很大作用，二者联合监测有互补性，可提高诊断的早期性特异性准确性.
, 百拇医药
陈艳宁,姜季, 李焕春,钟志.CA199和CEA联合检测对肠道恶性肿瘤术后复发的诊断价值.世界华人消化杂志 2005;13(12):1472-1473
Zhang L, Li SN, Wang XN. CEA and AFP expression in human hepatomacells transfected with antisense IGF-I gene.
World J Gastroenterol 1998;4:30-32
3 Marchena J, Acosta MA, Garcia-Anguiano F, Simpson H, Cruz F. Use ofthe preoperative levels of CEA in patients
with colorectal cancer. Hepatogastroenterology 2003;50:1017-1020
, 百拇医药
4 Grotowski M, Maruszynski M, Piechota W. Usefulness of preoperativeassay CEA and CA 19-9 in colorectal cancer
patients. Pol Merkuriusz Lek 2001;11:476-479
5 Yu JK, Yang MQ, Jiang TJ, Zheng S. The optimal combination of serumtumor markers with bioinformatics in
diagnosis of colorectal carcinoma. ZhejiangDaxue Xuebao Yixueban 2004;33:407-410
6 Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Jarvinen H,Haglund C. CEA, CA 242, CA 19-9,CA 72-4 and hCGbeta in the diagnosisof recurrent colorectal cancer. Tumour Biol 2004;25:228-234
, 百拇医药
7 Grotowski M. Antigens (CEA and CA 19-9) in diagnosis and prognosiscolorectal cancer.
Pol Merkuriusz Lek 2002;12:77-80
8 Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H,Kodaira S, Okajima K, Nakazato H. Tumor
Marker Committee. The usefulness ofCEA and/or CA19-9 in monitoring for recurrence in gastric cancerpatients:
a prospective clinical study. GastricCancer 2003;6:142-145
, http://www.100md.com
9 Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R.Multivariate analysis of the prognostic value of
CEA and CA 19-9 serum levels incolorectal cancer. Anticancer Res 2000;20:5195-5198
10 Wang WS, Lin JK, Chiou TJ, Liu JH, Fan FS, Yen CC, Lin TC, Jiang JK,Yang SH, Wang HS, Chen PM. CA19-9 as the
most significant prognosticindicator of metastatic colorectal cancer. Hepatogastroenterology 2002;49:160-164
, http://www.100md.com
11 Takahashi Y. Gastrointestinal cancer. Gan To Kagaku Ryoho 2004;31:1275-1279
12 Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, ChangSC. Is it reasonable to add preoperative
serum level of CEA and CA19-9to staging for colorectal cancer? J Surg Res 2005;124:169-174
13 Morita S, Nomura T, Fukushima Y, Morimoto T, Hiraoka N, Shibata N.Does serum CA19-9 play a practical role in
, 百拇医药
the management of patientswith colorectal cancer? Dis Colon Rectum 2004;47:227-232
14 Zheng CX, Zhan WH, Zhao JZ, Zheng D, Wang DP, He YL, Zheng ZQ. Theprognostic value of preoperative serum
levels of CEA, CA19-9 andCA72-4 in patients with colorectal cancer. World J Gastroenterol 2001;7:431-434
15 宁阳, 黄文萱. CEA单克隆抗体在肿瘤诊断和治疗中的应用及进展.单克隆抗体通讯 1995;11:62-64
16 许国强, 黄怀德, 王开明.CA199在胃肠肿瘤组织中的测定及其意义.肿瘤研究与临床 1997;9:170-172
编辑 王瑾晖 审读 张海宁, http://www.100md.com( 陈艳宁, 姜 季, 李焕春, 钟 志)
姜季, 哈尔滨医科大学附属肿瘤医院核医学 黑龙江省哈尔滨市 150040
通讯作者:陈艳宁,150040, 黑龙江省哈尔滨市南岗区哈平路150号,哈尔滨医科大学附属肿瘤医院检验科. duzj01@hit.edu.cn
电话: 0451-86627491
收稿日期:2005-04-11 接受日期:2005-04-27
摘要目的:探讨低聚糖类抗原(CA199)和癌胚抗原(CEA)两种标志物联合检测对肠道恶性肿瘤术后复发转移的早期诊断价值.
, http://www.100md.com
方法:微粒子酶免发光法(MEIA)测定32例肠道恶性肿瘤患者外周血CA199和CEA，实验结果结合临床资料进行分析.
结果:肠道恶性肿瘤术后患者转移复发组CEA、CA199明显高于无复发转移组(P<0.05).平行实验灵敏度为:78.52%;特异性:84.21%;阳性预测值:77.27%;临床疑似率:78.13%;系列实验灵敏度:60.00%;特异性:94.12%;阳性预测值:90.00%;临床疑似率:81.25%.单项测定结果:CEA灵敏度为60.71%;特异性:86.84%;阳性预测值:77.27%;临床疑似率:71.87%.CA199灵敏度为64.29;特异性:94.74%;阳性预测值:90.00%;临床疑似率:84.38%.
结论:外周血CA199与CEA对肠道恶性肿瘤术后转移复发的早期诊断有很大作用，二者联合监测有互补性，可提高诊断的早期性特异性准确性.
, 百拇医药
陈艳宁,姜季, 李焕春,钟志.CA199和CEA联合检测对肠道恶性肿瘤术后复发的诊断价值.世界华人消化杂志 2005;13(12):1472-1473
Zhang L, Li SN, Wang XN. CEA and AFP expression in human hepatomacells transfected with antisense IGF-I gene.
World J Gastroenterol 1998;4:30-32
3 Marchena J, Acosta MA, Garcia-Anguiano F, Simpson H, Cruz F. Use ofthe preoperative levels of CEA in patients
with colorectal cancer. Hepatogastroenterology 2003;50:1017-1020
, 百拇医药
4 Grotowski M, Maruszynski M, Piechota W. Usefulness of preoperativeassay CEA and CA 19-9 in colorectal cancer
patients. Pol Merkuriusz Lek 2001;11:476-479
5 Yu JK, Yang MQ, Jiang TJ, Zheng S. The optimal combination of serumtumor markers with bioinformatics in
diagnosis of colorectal carcinoma. ZhejiangDaxue Xuebao Yixueban 2004;33:407-410
6 Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Jarvinen H,Haglund C. CEA, CA 242, CA 19-9,CA 72-4 and hCGbeta in the diagnosisof recurrent colorectal cancer. Tumour Biol 2004;25:228-234
, 百拇医药
7 Grotowski M. Antigens (CEA and CA 19-9) in diagnosis and prognosiscolorectal cancer.
Pol Merkuriusz Lek 2002;12:77-80
8 Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H,Kodaira S, Okajima K, Nakazato H. Tumor
Marker Committee. The usefulness ofCEA and/or CA19-9 in monitoring for recurrence in gastric cancerpatients:
a prospective clinical study. GastricCancer 2003;6:142-145
, http://www.100md.com
9 Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R.Multivariate analysis of the prognostic value of
CEA and CA 19-9 serum levels incolorectal cancer. Anticancer Res 2000;20:5195-5198
10 Wang WS, Lin JK, Chiou TJ, Liu JH, Fan FS, Yen CC, Lin TC, Jiang JK,Yang SH, Wang HS, Chen PM. CA19-9 as the
most significant prognosticindicator of metastatic colorectal cancer. Hepatogastroenterology 2002;49:160-164
, http://www.100md.com
11 Takahashi Y. Gastrointestinal cancer. Gan To Kagaku Ryoho 2004;31:1275-1279
12 Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, ChangSC. Is it reasonable to add preoperative
serum level of CEA and CA19-9to staging for colorectal cancer? J Surg Res 2005;124:169-174
13 Morita S, Nomura T, Fukushima Y, Morimoto T, Hiraoka N, Shibata N.Does serum CA19-9 play a practical role in
, 百拇医药
the management of patientswith colorectal cancer? Dis Colon Rectum 2004;47:227-232
14 Zheng CX, Zhan WH, Zhao JZ, Zheng D, Wang DP, He YL, Zheng ZQ. Theprognostic value of preoperative serum
levels of CEA, CA19-9 andCA72-4 in patients with colorectal cancer. World J Gastroenterol 2001;7:431-434
15 宁阳, 黄文萱. CEA单克隆抗体在肿瘤诊断和治疗中的应用及进展.单克隆抗体通讯 1995;11:62-64
16 许国强, 黄怀德, 王开明.CA199在胃肠肿瘤组织中的测定及其意义.肿瘤研究与临床 1997;9:170-172
编辑 王瑾晖 审读 张海宁, http://www.100md.com( 陈艳宁, 姜 季, 李焕春, 钟 志)
